HOLL - Hollywood Media Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.00 (0.00%)
As of 10:55AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.19
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume28,346
Market Cap3.065M
PE Ratio (TTM)0.69
EPS (TTM)0.28
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-04-02
1y Target Est2.50
Trade prices are not sourced from all markets
  • NewStem Announces $4 million Seed Investment
    PR Newswirelast month

    NewStem Announces $4 million Seed Investment

    JERUSALEM, July 16, 2018 /PRNewswire/ --  NewStem Ltd., a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness, today announced a $4 million seed financing from a publicly-traded US-based company to be named NovelStem International Corp. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University. Drug resistance is a major cause of treatment failure in cancer chemotherapy.

  • GlobeNewswirelast month

    Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy Resistance

    Plans to Rename Company NovelStem International Corp. JERUSALEM and BOCA RATON, Fla., July 16, 2018 (GLOBE NEWSWIRE) -- Hollywood Media Corp. (OTC Pink:HOLL) (HMC) today announced the strategic transformation of the Company, its management and Board through an initial $2 million investment in Jerusalem, Israel-based NewStem Ltd. and a refocusing of HMC on the substantial commercial potential of NewStem’s novel diagnostic technology which can predict patients’ resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy.

  • We're sorry this is all we were able to find about this topic.